Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel.
Single-cell transcriptomes reveal the mechanism for a breast cancer prognostic gene panel.
复制标题
DOI：
10.18632/oncotarget.26044
复制
发表时间：
2018-09-07
期刊：
影响因子：
--
通讯作者：
Zhong JF
中科院分区：
文献类型：
--
作者：
Li SC;Stucky A;Chen X;Kabeer MH;Loudon WG;Plant AS;Torno L;Nangia CS;Cai J;Zhang G;Zhong JF
MammaPrint®标签对乳腺癌的临床益处已有充分记载;然而，这些基因如何与细胞周期扰动相关尚未得到很好的确定。我们的单细胞转录组作图（算法）提供了细胞周期期间所有单个基因的精细扰动的细节，提供了任何给定人类基因的细胞周期阶段特定景观的视图。具体来说，我们发现70个MammaPrint®特征基因中有38个（54%）在细胞周期的特定阶段受到干扰。MammaPrint®特征板通过测量特定乳腺癌样本的细胞周期活性来获得其临床预后能力。这种MammaPrint®标记的细胞周期阶段指数表明，对来自肿瘤的细胞周期指数的测量可以发展成为乳腺癌以外的各种类型癌症的预后工具，通过靶向癌细胞的细胞周期的特定阶段潜在地改善治疗。
The clinical benefits of the MammaPrint® signature for breast cancer is well documented; however, how these genes are related to cell cycle perturbation have not been well determined. Our single-cell transcriptome mapping (algorithm) provides details into the fine perturbation of all individual genes during a cell cycle, providing a view of the cell-cycle-phase specific landscape of any given human genes. Specifically, we identified that 38 out of the 70 (54%) MammaPrint® signature genes are perturbated to a specific phase of the cell cycle. The MammaPrint® signature panel derived its clinical prognosis power from measuring the cell cycle activity of specific breast cancer samples. Such cell cycle phase index of the MammaPrint® signature suggested that measurement of the cell cycle index from tumors could be developed into a prognosis tool for various types of cancer beyond breast cancer, potentially improving therapy through targeting a specific phase of the cell cycle of cancer cells.